[Ip-health] News: Hindu Business Line- New export norm to identify origin, maker of drugs

Terri - Louise Beswick Terri at haiweb.org
Mon Sep 27 01:35:38 PDT 2010

New export norm to identify origin, maker of drugs

Hyderabad, Sept. 24


The Union Government will announce new regulations for pharmaceutical
exports soon to clearly identify the origin of the product and its


"The idea behind the move is to tackle the campaigns on the quality of
Indian generics and their wrongful identification with counterfeit
drugs," Mr Rajeev Kher, Joint Secretary, Department of Commerce, told
newspersons on the sidelines of a pharma CEO conclave organised by
Pharmaceutical Export Promotion Council here on Friday.


The 'confusion' over the difference between the generics and
counterfeits/substandard drugs has resulted in some Indian pharma
exports to Latin America and Africa being detained in Europe, he


"The introduction of traceability for drug exports will solve this
problem as it helps identify the origin of the product," he said.




The Government is also concerned at the possibility of Indian drug
companies "being pushed/forced" to go for mergers/acquisitions by the
global majors.


"We want to protect the uniqueness of the Indian pharma industry in
terms of pricing and quality. If mergers and acquisitions are market
driven, we have no problem. But if they are forced because of financial
constraints, the Government may have to take policy intervention. The
Government has commissioned a study to analyse the pattern of M&As. The
report is likely within three months. Further course of action will be
decided after that," the officials said.


To ensure availability of funds for the pharma companies, a platform
would be created by the Government.


"A common platform to bring together banks, financial institutions and
pharma companies would be organised in October," he said.


Addressing participants in the meet earlier, Dr S. M. Jharwal, Chairman,
National Pharmaceutical Pricing Authority, said the industry had to
"live with price controls".



More information about the Ip-health mailing list